About Tangen Biosciences
Tangen Biosciences is a private company based in Branford, Connecticut. It has reported $20,424,747 raised in five offerings on Form D since December 2015. Its chief executive is Richard Birkmeyer, PhD.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| May 26, 2023 | Jun 6, 2023 | $464,767of $2.5M target | 9 | $51,641 | Debt, Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Jun 19, 2020 | Jul 1, 2020 | $11,239,731of $20.0M target | 39 | $288K | Equity, Debt, Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Mar 14, 2019 | Mar 22, 2019 | $6,689,846of $11.0M target | 29 | $230K | Equity, Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Not yet | Nov 2, 2016 | $0of $8.0M target | 0 | — | EquityRule 506(c) | Form D ↗ |
| Dec 14, 2015 | Dec 28, 2015 | $2,030,403of $3.0M target | 8 | $253K | EquityRule 506(b) | Form D ↗ |
| Total, five offerings | $20,424,747 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Tangen Biosciences's Form D filed Jun 6, 2023.
AL
Alan Levin
Director
RP
Richard Birkmeyer, PhD
President and CEO, director
VK
Vance Kershner
Director
DW
Daniel Wagner
Director
CM
Christopher McLeod
Director
JD
John Davidson
Executive officer and director
Earlier filings also listed Christopher Benoit (director, last listed Jul 2020), Brian Chirico (executive officer, last listed Jul 2020) and John Nobile (director, last listed Nov 2016).